How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors
Author:
Affiliation:
1. Louisiana Center for Bleeding and Clotting Disorders, Tulane University Medical Center, New Orleans, LA; and
2. Washington Center for Bleeding Disorders, Bloodworks Northwest, Seattle, WA
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/126/2/153/1389752/153.pdf
Reference75 articles.
1. Immune tolerance: high-dose regimen.;Brackmann,2002
2. Kasper CK Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Treatment of Hemophilia Monograph Series, no. 34; September 2004. Available at: http://www1.wfh.org/publication/files/pdf-1178.pdf. Accessed August 29, 2014
3. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study.;Gouw;Blood,2007
4. Factor IX inhibitors and anaphylaxis in hemophilia B.;Warrier;J Pediatr Hematol Oncol,1997
5. Diagnosis and quantification of factor VIII inhibitors.;Verbruggen;Haemophilia,2010
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Hemoperitoneum as a Life-Threatening Complication of an Acute Cholecystitis in a Patient with Hemophilia A with Inhibitors: A Case Report;Healthcare;2022-08-30
2. A multicentre real-world data study to assess the bleeding rate and management of patients with haemophilia A and factor VIII inhibitors in Argentina;Blood Coagulation & Fibrinolysis;2021-08-23
3. First observation of inhibitor development against efmoroctocog alfa in France;Transfusion and Apheresis Science;2021-08
4. Thrombin-like serine protease, antiquorin from Euphorbia antiquorum latex induces platelet aggregation via PAR1-Akt/p38 signaling axis;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2021-03
5. ST‐Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII;Haemophilia;2019-11-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3